TY - JOUR
AU - Wang, Lu-ning
AB - CNS Drugs (2014) 28:63–68 DOI 10.1007/s40263-013-0124-4 SYSTEMATIC REVIEW Mitochondrial Enhancement for Neurodegenerative Movement Disorders: A Systematic Review of Trials Involving Creatine, Coenzyme Q10, Idebenone and Mitoquinone Jia Liu Lu-ning Wang Published online: 16 November 2013 Springer International Publishing Switzerland 2013 Abstract Conclusions There is insufficient evidence to support the Background Neurodegenerative movement disorders use of mitochondrial enhancement in patients with neuro- mainly include Parkinson’s disease (PD), atypical par- degenerative movement disorders. More well-designed kinsonisms, Huntington’s disease (HD), and Friedreich’s RCTs with large samples are required for further ataxia (FA). With mitochondrial dysfunction observed in confirmation. these diseases, mitochondrial enhancement such as crea- tine, coenzyme Q10 (CoQ10) and its analogues (idebenone and mitoquinone) has been regarded as a potential 1 Introduction treatment. Aim In this paper, we systematically analysed and sum- Neurodegenerative diseases (NDs) are generally acknowl- edged as a group of neurological disorders with degeneration marized the efficacy of mitochondrial enhancement in and loss of neurons, and most are with pathological accu- improving motor and other symptoms in neurodegenerative movement disorders. mulations in the brain. Clinical movement disorders are the main symptoms in some NDs, such as Parkinson’s disease Methods We searched the electronic databases PubMed, EMBASE, CINAHL, Cochrane 
TI - Mitochondrial Enhancement for Neurodegenerative Movement Disorders: A Systematic Review of Trials Involving Creatine, Coenzyme Q10, Idebenone and Mitoquinone
JF - CNS Drugs
DO - 10.1007/s40263-013-0124-4
DA - 2013-11-16
UR - https://www.deepdyve.com/lp/springer-journals/mitochondrial-enhancement-for-neurodegenerative-movement-disorders-a-athI3TSnhB
SP - 63
EP - 68
VL - 28
IS - 1
DP - DeepDyve
ER -